EUVIMEDObjevte EUVIMED
Multizentrische Studie

Multicenter analysis of [123I/131I]I-mIBG imaging in pediatric neuroblastoma — effective dose estimation

Małgorzata Poniatowska-Roszkowska iD, Mark O Wielpütz iD, Hanna Piwowarska-Bilska iD, Sara Kurkowska iD, Agnieszka Marciniak, Anna Górnik, Jacek Iwanowski, Esam T Ahmed Mohamed, Anna Synakiewicz iD, Joanna Stefanowicz iD, Aleksandra Wieczorek iD, Tabea Troschke and 2 more

Nuclear Medicine Review · 2026

DOI: 10.5603/nmr.113604 ↗

At a glance

Multizentrische Studie in Nuclear Medicine Review, 2026. Written by Małgorzata Poniatowska-Roszkowska and 13 co-authors. Institution: Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. malgorzata.poniatowska@pum.edu.pl. Major MEDLINE topics: Neuroblastoma, 3-Iodobenzylguanidine, Iodine Radioisotopes, Radiation Dosage.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Neuroblastoma is the most common extracranial solid tumor in children, predominantly affecting patients under 10 years. Due to therapeutic challenges, most patients are treated in specialized pediatric oncology centers. [123I/131I]I-mIBG scintigraphy plays a crucial role in the diagnosis, staging, assessment of treatment response and long-term follow-up of patients with neuroblastoma. This study is part of the TEMICARE 2.0 project, which aims to improve the health and psychosocial well-being of patients with neuroblastoma in the Pomerania Euroregion. The aim of this study was to retrospectively analyze the use of [123I/131I]I-mIBG imaging in the diagnosis of neuroblastoma in children and to compare clinical practice at participating centers. Material and methods. Patients with suspected or confirmed neuroblastoma who underwent [123I] or [131I]I-mIBG scintigraphy at two pediatric oncology centers in Poland and Germany from 2019–2024 were retrospectively included. Acquisition parameters were collected in a standardized manner.

Results

A total of 320 examinations were performed in 88 patients. At Site 1, 190 studies were performed using [131I]I-mIBG, whereas 130 studies using [123I]I-mIBG were conducted at Site 2. The mean age of the patients was 3 years (range: 1 month–14 years). The average number of examinations per patient was four. The mean cumulative effective dose delivered to patients during all examinations with [123I]I-mIBG was 123 mSv, compared with 207 mSv for [131I]I-mIBG, representing an approximately 40% lower dose with [123I]I-mIBG. Conclusions. [123I]I-mIBG imaging is an essential tool for disease staging and monitoring treatment response in patients with neuroblastoma. Current guidelines recommend the use of [123I]I-mIBG because of its superior diagnostic performance and more favorable radiation dosimetry profile. However, the availability of this radiopharmaceutical remains limited due to higher costs and the logistical challenges associated with transportation to centers located far from production facilities.

Subjects

MeSH terms (MEDLINE)

Neuroblastoma3-IodobenzylguanidineIodine RadioisotopesRadiation DosageHumansFemaleChildChild, PreschoolInfantMaleRetrospective StudiesRadionuclide ImagingAdolescent

Author keywords

[123I]I-mIBG[131I]I-mIBGneuroblastomascintigraphy

Substances

3-IodobenzylguanidineIodine RadioisotopesIodine-131

Authors and institutions

  • Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany. malgorzata.poniatowska@pum.edu.pl.
  • Department of Diagnostic and Interventional Radiology, University Medicine Greifswald, Greifswald, Germany. malgorzata.poniatowska@pum.edu.pl.
  • Department of Nuclear Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland. malgorzata.poniatowska@pum.edu.pl.
  • Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany.
  • Department of Diagnostic and Interventional Radiology, University Medicine Greifswald, Greifswald, Germany.
  • Department of Nuclear Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland.

ORCID profiles: Małgorzata Poniatowska-Roszkowska, Mark O Wielpütz, Hanna Piwowarska-Bilska, Sara Kurkowska, Anna Synakiewicz, Joanna Stefanowicz, Aleksandra Wieczorek, Holger N Lode, Bożena Birkenfeld

Cite

APA

Poniatowska-Roszkowska, M., Wielpütz, M. O., Piwowarska-Bilska, H., Kurkowska, S., Marciniak, A., Górnik, A., Iwanowski, J., Ahmed Mohamed, E. T., Synakiewicz, A., Stefanowicz, J., Wieczorek, A., Troschke, T., Lode, H. N., & Birkenfeld, B. (2026). Multicenter analysis of [123I/131I]I-mIBG imaging in pediatric neuroblastoma — effective dose estimation. Nuclear Medicine Review. https://doi.org/10.5603/nmr.113604

Vancouver

Poniatowska-Roszkowska M, Wielpütz MO, Piwowarska-Bilska H, Kurkowska S, Marciniak A, Górnik A, et al. Multicenter analysis of [123I/131I]I-mIBG imaging in pediatric neuroblastoma — effective dose estimation. Nuclear Medicine Review. 2026. doi:10.5603/nmr.113604

BibTeX
@article{PoniatowskaRoszkowska2026,
  author = {Poniatowska-Roszkowska, Małgorzata and Wielpütz, Mark O and Piwowarska-Bilska, Hanna and Kurkowska, Sara and Marciniak, Agnieszka and Górnik, Anna and Iwanowski, Jacek and Ahmed Mohamed, Esam T and Synakiewicz, Anna and Stefanowicz, Joanna and Wieczorek, Aleksandra and Troschke, Tabea and Lode, Holger N and Birkenfeld, Bożena},
  title = {Multicenter analysis of [123I/131I]I-mIBG imaging in pediatric neuroblastoma — effective dose estimation},
  journal = {Nuclear Medicine Review},
  year = {2026},
  doi = {10.5603/nmr.113604}
}
Start for free →